ASLAN Pharmaceuticals (ASLN) Competitors

ASLAN Pharmaceuticals logo
$0.60 0.00 (0.00%)
As of 11/6/2026

ASLN vs. TRAW, GELS, GRI, NCNA, and RDHL

Should you buy ASLAN Pharmaceuticals stock or one of its competitors? ASLAN Pharmaceuticals's main competitors and comparable companies include Traws Pharma (TRAW), Gelteq (GELS), GRI Bio (GRI), NuCana (NCNA), and Redhill Biopharma (RDHL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does ASLAN Pharmaceuticals compare to Traws Pharma?

Traws Pharma (NASDAQ:TRAW) and ASLAN Pharmaceuticals (NASDAQ:ASLN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, profitability, valuation, dividends and risk.

Traws Pharma currently has a consensus target price of $1.00, indicating a potential upside of 334.78%. Given Traws Pharma's stronger consensus rating and higher probable upside, equities research analysts plainly believe Traws Pharma is more favorable than ASLAN Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Traws Pharma
1 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.80
ASLAN Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

8.0% of Traws Pharma shares are held by institutional investors. Comparatively, 58.8% of ASLAN Pharmaceuticals shares are held by institutional investors. 8.7% of Traws Pharma shares are held by company insiders. Comparatively, 4.7% of ASLAN Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Traws Pharma had 11 more articles in the media than ASLAN Pharmaceuticals. MarketBeat recorded 11 mentions for Traws Pharma and 0 mentions for ASLAN Pharmaceuticals. Traws Pharma's average media sentiment score of 0.92 beat ASLAN Pharmaceuticals' score of 0.00 indicating that Traws Pharma is being referred to more favorably in the media.

Company Overall Sentiment
Traws Pharma Positive
ASLAN Pharmaceuticals Neutral

ASLAN Pharmaceuticals' return on equity of -8,454.87% beat Traws Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Traws PharmaN/A -23,868.92% -182.69%
ASLAN Pharmaceuticals N/A -8,454.87%-121.60%

Traws Pharma has a beta of 1.67, meaning that its share price is 67% more volatile than the broader market. Comparatively, ASLAN Pharmaceuticals has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market.

Traws Pharma has higher earnings, but lower revenue than ASLAN Pharmaceuticals. Traws Pharma is trading at a lower price-to-earnings ratio than ASLAN Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Traws Pharma$2.79M1.27$9.17M-$1.58N/A
ASLAN Pharmaceuticals$12M0.10-$44.22M-$21.92N/A

Summary

Traws Pharma beats ASLAN Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does ASLAN Pharmaceuticals compare to Gelteq?

ASLAN Pharmaceuticals (NASDAQ:ASLN) and Gelteq (NASDAQ:GELS) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk, media sentiment and dividends.

58.8% of ASLAN Pharmaceuticals shares are held by institutional investors. 4.7% of ASLAN Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ASLAN Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Gelteq
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Gelteq has lower revenue, but higher earnings than ASLAN Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ASLAN Pharmaceuticals$12M0.10-$44.22M-$21.92N/A
Gelteq$240K13.46-$4.30MN/AN/A

In the previous week, Gelteq had 2 more articles in the media than ASLAN Pharmaceuticals. MarketBeat recorded 2 mentions for Gelteq and 0 mentions for ASLAN Pharmaceuticals. Gelteq's average media sentiment score of 0.31 beat ASLAN Pharmaceuticals' score of 0.00 indicating that Gelteq is being referred to more favorably in the news media.

Company Overall Sentiment
ASLAN Pharmaceuticals Neutral
Gelteq Neutral

Gelteq's return on equity of 0.00% beat ASLAN Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
ASLAN PharmaceuticalsN/A -8,454.87% -121.60%
Gelteq N/A N/A N/A

ASLAN Pharmaceuticals has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market. Comparatively, Gelteq has a beta of -0.37, meaning that its stock price is 137% less volatile than the broader market.

Summary

Gelteq beats ASLAN Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

How does ASLAN Pharmaceuticals compare to GRI Bio?

GRI Bio (NASDAQ:GRI) and ASLAN Pharmaceuticals (NASDAQ:ASLN) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability and earnings.

In the previous week, GRI Bio had 6 more articles in the media than ASLAN Pharmaceuticals. MarketBeat recorded 6 mentions for GRI Bio and 0 mentions for ASLAN Pharmaceuticals. GRI Bio's average media sentiment score of 0.83 beat ASLAN Pharmaceuticals' score of 0.00 indicating that GRI Bio is being referred to more favorably in the media.

Company Overall Sentiment
GRI Bio Positive
ASLAN Pharmaceuticals Neutral

GRI Bio presently has a consensus price target of $21.00, indicating a potential upside of 1,775.00%. Given GRI Bio's stronger consensus rating and higher possible upside, equities research analysts plainly believe GRI Bio is more favorable than ASLAN Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GRI Bio
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
ASLAN Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

GRI Bio has higher earnings, but lower revenue than ASLAN Pharmaceuticals. GRI Bio is trading at a lower price-to-earnings ratio than ASLAN Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GRI BioN/AN/A-$11.96M-$3.21N/A
ASLAN Pharmaceuticals$12M0.10-$44.22M-$21.92N/A

GRI Bio's return on equity of -87.61% beat ASLAN Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
GRI BioN/A -87.61% -75.89%
ASLAN Pharmaceuticals N/A -8,454.87%-121.60%

GRI Bio has a beta of -1.13, suggesting that its stock price is 213% less volatile than the broader market. Comparatively, ASLAN Pharmaceuticals has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market.

34.0% of GRI Bio shares are owned by institutional investors. Comparatively, 58.8% of ASLAN Pharmaceuticals shares are owned by institutional investors. 0.6% of GRI Bio shares are owned by company insiders. Comparatively, 4.7% of ASLAN Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

GRI Bio beats ASLAN Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does ASLAN Pharmaceuticals compare to NuCana?

NuCana (NASDAQ:NCNA) and ASLAN Pharmaceuticals (NASDAQ:ASLN) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, media sentiment, profitability, valuation and analyst recommendations.

NuCana's return on equity of -51.18% beat ASLAN Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
NuCanaN/A -51.18% -41.16%
ASLAN Pharmaceuticals N/A -8,454.87%-121.60%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NuCana
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
ASLAN Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, NuCana's average media sentiment score of 1.50 beat ASLAN Pharmaceuticals' score of 0.00 indicating that NuCana is being referred to more favorably in the media.

Company Overall Sentiment
NuCana Very Positive
ASLAN Pharmaceuticals Neutral

44.0% of NuCana shares are owned by institutional investors. Comparatively, 58.8% of ASLAN Pharmaceuticals shares are owned by institutional investors. 31.2% of NuCana shares are owned by company insiders. Comparatively, 4.7% of ASLAN Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

NuCana has a beta of 2.39, indicating that its share price is 139% more volatile than the broader market. Comparatively, ASLAN Pharmaceuticals has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market.

NuCana has higher earnings, but lower revenue than ASLAN Pharmaceuticals. NuCana is trading at a lower price-to-earnings ratio than ASLAN Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NuCanaN/AN/A-$38.71M-$4.18N/A
ASLAN Pharmaceuticals$12M0.10-$44.22M-$21.92N/A

Summary

NuCana beats ASLAN Pharmaceuticals on 8 of the 10 factors compared between the two stocks.

How does ASLAN Pharmaceuticals compare to Redhill Biopharma?

Redhill Biopharma (NASDAQ:RDHL) and ASLAN Pharmaceuticals (NASDAQ:ASLN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, media sentiment, valuation, risk and analyst recommendations.

In the previous week, Redhill Biopharma had 1 more articles in the media than ASLAN Pharmaceuticals. MarketBeat recorded 1 mentions for Redhill Biopharma and 0 mentions for ASLAN Pharmaceuticals. Redhill Biopharma's average media sentiment score of 0.00 equaled ASLAN Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Redhill Biopharma Neutral
ASLAN Pharmaceuticals Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Redhill Biopharma
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
ASLAN Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Redhill Biopharma has a beta of 4.93, indicating that its share price is 393% more volatile than the broader market. Comparatively, ASLAN Pharmaceuticals has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market.

7.2% of Redhill Biopharma shares are held by institutional investors. Comparatively, 58.8% of ASLAN Pharmaceuticals shares are held by institutional investors. 6.8% of Redhill Biopharma shares are held by insiders. Comparatively, 4.7% of ASLAN Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Redhill Biopharma has higher earnings, but lower revenue than ASLAN Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Redhill Biopharma$290K9.91-$430KN/AN/A
ASLAN Pharmaceuticals$12M0.10-$44.22M-$21.92N/A

Redhill Biopharma's return on equity of 0.00% beat ASLAN Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Redhill BiopharmaN/A N/A N/A
ASLAN Pharmaceuticals N/A -8,454.87%-121.60%

Summary

Redhill Biopharma beats ASLAN Pharmaceuticals on 8 of the 10 factors compared between the two stocks.

Get ASLAN Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ASLN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ASLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ASLN vs. The Competition

MetricASLAN PharmaceuticalsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1.23M$13.35B$7.59B$11.70B
Dividend YieldN/A2.60%2.48%4.65%
P/E Ratio-0.0326.9031.9926.76
Price / Sales0.107.098.405.53
Price / CashN/A15.5320.7221.66
Price / Book-0.095.304.423.65
Net Income-$44.22M$2.87B$3.51B$394.00M
7 Day PerformanceN/A-5.14%-5.44%-5.74%
1 Month PerformanceN/A-7.77%-8.62%-9.54%
1 Year PerformanceN/A-6.74%-1.31%-6.71%

ASLAN Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ASLN
ASLAN Pharmaceuticals
N/A$0.60
flat
N/AN/A$1.23M$12MN/A30
TRAW
Traws Pharma
2.2042 of 5 stars
$0.28
+13.9%
$1.00
+251.1%
-89.1%$4.38M$2.79MN/A7
GELS
Gelteq
0.9294 of 5 stars
$0.38
-9.5%
N/A-69.2%$4.08M$165.65KN/A18
GRI
GRI Bio
3.1421 of 5 stars
$1.82
-0.5%
$21.00
+1,053.8%
-97.6%$3.98MN/AN/A5
NCNA
NuCana
0.9594 of 5 stars
$0.93
-1.0%
N/A-78.6%$3.87MN/AN/A11

Related Companies and Tools


This page (NASDAQ:ASLN) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners